Compare Regeneron Pharmaceuticals Inc (REGN) vs Toronto-Dominion Bank (TD) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

TD trades at $120.52, down 0.91% on the day, with a neutral technical signal. The company reported strong Q3 2026 earnings of $2.74 EPS, beating estimates, driven by capital markets performance and cost controls. Revenue growth continues with 2025 revenue reaching $61.28B and net income margin of 33.51%. Analyst consensus is bullish with 9 buy ratings and no sell recommendations.

TD presents a compelling investment case with consistent earnings beats and strong profitability metrics. However, investors should monitor the volatile cash flow patterns and rising debt-to-asset ratio, which increased to 22.1 in 2024. The stock's current valuation at 17.85 P/E appears reasonable given the company's growth trajectory and dividend yield.